NxStage® to Report Fourth Quarter and Full Year 2011 Financial Results
January 20, 2012


Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
January 6, 2012


Synageva Biopharma Announces Pricing Of Public Offering Of Common Stock
January 5, 2012


Transcept Pharmaceuticals Announces FDA Approval of Intermezzo® (zolpidem tartrate sublingual tablet) C-IV For Use as Needed for the Treatment of Insomnia When a Middle-of-the-Night Awakening is Followed by Difficulty Returning to Sleep
November 23, 2011


Transcept Pharmaceuticals Reports Third Quarter 2011 Financial Results
November 10, 2011


Synageva BioPharma Announces Completion of Merger with Trimeris
November 3, 2011


NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
November 3, 2011


ISTA Pharmaceuticals Reports Third Quarter 2011 Financial Results
November 1, 2011


Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
August 30, 2011


Epocrates Reports 2011 Second Quarter Financial Results and Updated 2011 Guidance
August 9, 2011


Transcept Pharmaceuticals to Report Second Quarter 2011 Financial Results, and Host Conference Call on August 11, 2011
August 4, 2011


NxStage Reports Record Second Quarter 2011 Financial Results and Raises Revenue Guidance for 2011
August 3, 2011


ISTA Pharmaceuticals Reports Second Quarter 2011 Financial Results
July 28, 2011


Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
July 19, 2011


Concert Pharmaceuticals Announces Milestone Achievement in GlaxoSmithKline Collaboration
June 20 , 2011


ReShape Medical Announces Results Of Phase 1 U.S. Clinical Study For Weight Loss
June 17, 2011


Pearl Therapeutics Advances its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
June 16, 2011


Synageva Biopharma And Trimeris Announce Merger Agreement
June 13, 2011


Durata Therapeutics Announces Dalbavancin Production Capabilities and Signing of Global Manufacturing Agreement
June 6, 2011


FDA Grants Fast Track Designation to Tioga Pharmaceuticals’ Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
June 1, 2001


Prometheus Announces Agreement to be Acquired by Nestlé Health Science
May 24, 2011


Takeda to Acquire Nycomed
May 19, 2011


Pearl Therapeutics’ Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
May 18, 2011


Transcept Pharmaceuticals Reports First Quarter 2011 Financial Results
May 16, 2011


Neuronetics, Inc. Raises $30 Million in Series E Financing
May 16, 2011


New Trial Data Confirm Clinical Effectiveness and Good Adherence Rates with NeuroStar TMS Therapy in Patients with Major Depressive Disorder Treated in a Real World Practice Setting
May 14, 2011


Affymax® Reports First Quarter 2011 Financial Results
May 11, 2011


iRhythm Technologies, Inc. Raises $15 Million Series C Equity Round
May 4, 2011


ISTA Pharmaceuticals Reports First Quarter 2011 Financial Results
May 4, 2011


Epocrates to Report 2011 First Quarter Financial Results and Host Conference Call on May 10, 2011
April 26, 2011


Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
April 25, 2011


NxStage® to Report First Quarter Fiscal 2011 Financial Results
April 12, 2011


Convergence Pharmaceuticals Announces Phase I Trial Start of CNV2197944 for Chronic Pain
April 12, 2011


Presidio Pharmaceuticals, Inc. Announces Positive Results in a Phase 1b Clinical Trial of PPI-461, a Novel, Potent Broadly-Active Hepatitis C Virus (HCV) Inhibitor
March 30, 2011


Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study
March 29, 2011


Epocrates Reports 2010 Fourth Quarter and Full-Year Financial Results and Provides 2011 Outlook
March 29, 2011


Transcept Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
March 16, 2011


Affymax® Reports Year End 2010 Financial Results
March 10, 2011


Nycomed’s novel COPD therapy roflumilast receives FDA approval
March 1, 2011


HHS awards contracts to develop new flu vaccine technology
February 28, 2011


ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
February 23, 2011


NxStage® Reports Fourth Quarter and Full-Year 2010 Financial Results; Revenue Growth Exceeds Company Guidance
February 17, 2011


Versartis Completes $21 Million Series B Financing
February 16, 2011


Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
February 14, 2011


Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
February 10, 2011


Epocrates, Inc. Announces Pricing of Initial Public Offering
February 2, 2011


Transcept Pharmaceuticals Resubmits Intermezzo® New Drug Application for the Treatment of Middle of the Night Awakenings
January 18, 2011


Hologic Acquires Interlace Medical
January 7, 2011


Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
December 14, 2010


ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
December 14, 2010


Pearl Therapeutics’ PT003 Combination Therapy for COPD Demonstrates Superior Bronchodilation Compared to Spiriva® and Foradil® in Randomized Phase 2b Study
December 1, 2010


ISTA Pharmaceuticals Granted Three-Year Market Exclusivity for BROMDAY™
November 17, 2010


Pearl Therapeutics Raises $69 Million Series C Financing
October 19, 2010


Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
October 19, 2010


ISTA Pharmaceuticals Receives FDA Approval for BROMDAY™
October 16, 2010


World Heart Corp. to Raise $25.3 Million in Private Placement
October 14, 2010


Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
October 12, 2010


ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
October 06, 2010


New Leaf Venture Partners Invests in $35.4 (GBP 22.4) Million Series A Financing of Convergence Pharmaceuticals
October 5, 2010


BioRelix Enters Antibacterial Collaboration with Merck
October 4, 2010


New Randomized Controlled Trial Supports Efficacy And Safety Of Spiracur SNaP Wound Care System
September 27, 2010


First European Filing for Marketing Approval of Osteoporosis Drug
September 21, 2010


Daxas® (roflumilast) data analysis shows reduction in harmful lung attacks
September 19, 2010


Relypsa Raises $70 Million in Series B Financing
September 13, 2010


Neuronetics selected by World Economic Forum as 2011 Technology Pioneer
September 1, 2010


Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes
August 25, 2010


Oxford Immunotec announces US FDA approval of PMA supplement for the use of the T-Cell Xtend® reagent
August 11, 2010


WorldHeart Receives FDA Approval to Add Clinical Sites in Levacor™ VAD Bridge-to-Transplant Study
July 27, 2010


Epocrates, Inc. Files Registration Statement for Proposed Initial Public Offering
July 16, 2010


Presidio Pharmaceuticals, Inc. Successfully Completes Phase 1a Clinical Trial of PPI-461, a Potent, New Hepatitis C Virus (HCV) Inhibitor
July 14, 2010


Synageva Biopharma Receives Orphan Drug Designation for SBC-102 for Lysosomal Acid Lipase Deficiency
July 7, 2010


ISTA Pharmaceuticals Announces Phase III Results For Once-Daily Topical Xibrom™ 0.09%
July 1, 2010


Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
June 28, 2010


Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
June 28, 2010


Olympus to Acquire Spiration, Inc., a U.S. Pulmonary Device Company, as a Consolidated Subsidiary
June 25, 2010


Tioga Pharmaceuticals Begins Phase 3 Trial of Asimadoline in Irritable Bowel Syndrome
June 3, 2010


Sandoz completes acquisition of Oriel Therapeutics, strengthening potential for global leadership in respiratory
June 3, 2010


Presidio Pharmaceuticals, Inc. Selects Second Clinical Candidate from Hepatitis C Virus NS5A Inhibitor Program
May 26, 2010


Spiration Announces Positive Results of European Study Evaluating Safety and Effectiveness of Bronchial Valve Treatment for Severe Emphysema
May 19, 2010


Altura Medical Completes $20 Million Round of Financing
May 18, 2010


Pearl Therapeutics’ Data for its Combination Bronchodilator Product, PT003, Support the Potential for Improvement in the Treatment of Patients with COPD
May 18, 2010


Nycomed and Forest Laboratories receive complete FDA response letter for Roflumilast – no additional patient trials were requested
May 17, 2010


Prometheus Unveils Novel Approach for Predicting Risk of Disease Progression in Patients with Crohn’s Disease
May 3, 2010


Oxford Immunotec Closes Second Tranche of $26 Million Series D Financing Led by New Leaf Venture Partners
April 30, 2010


GE Healthcare and Nycomed to Form Joint Venture to Sell, Market and Distribute Medical Diagnostic Contrast Agents in Russia and CIS
April 27, 2010


VaxInnate’s VAX125 Seasonal Flu Vaccine Shown Safe and Highly Immunogenic in Phase II Study of Elderly Subjects
April 27, 2010


Presidio Pharmaceuticals, Inc. Initiates First-in-Human Clinical Trial of PPI-461, an Investigational NS5A Inhibitor for HCV
April 27, 2010


Nycomed and Merck & Co., Inc., Announce Commercialization Agreements for Daxas® in Europe and Canada
April 26, 2010


Nycomed’s Novel Anti-Inflammatory Therapy Daxas® (Roflumilast) Recommended for Approval in the European Union for Patients with COPD
April 23, 2010


Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD
April 19, 2010


WorldHeart Announces Levacor VAD Implant at Inova Fairfax Hospital, Virginia
April 13, 2010


NxStage® Expands Streamline® Blood Tubing Set and MasterGuard® Needle Supply Agreement with Renal Advantage Inc.
April 12, 2010


Nycomed and Baxter receive FDA approval for TachoSil®, an adjunct to haemostasis in cardiovascular surgery
April 6, 2010


Tioga Pharmaceuticals Receives Special Protocol Assessment Agreement from FDA for Phase 3 Trials of Asimadoline in Irritable Bowel Syndrome
April 5, 2010


Concert Pharmaceuticals Granted Patent for Deuterated Paroxetine Compounds, Including CTP-347
March 31 , 2010


Interlace Medical Initiates Clinical Trial of Myosuretm for Office-Based Treatment of Submucosal Fibroids
March 30, 2010


Pearl Therapeutics Announces Positive Results From Phase 1 Trial of Pt003, a Bronchodilator Combination Therapeutic for Chronic Obstructive Pulmonary Disease, and Initiation of Phase 2b Trial
March 29, 2010


Transcept Pharmaceuticals Updates Plan for Intermezzo® NDA Resubmission Following Teleconference With the FDA
March 24, 2010


Oxford Immunotec announces contract with Scancell Ltd to measure T cell
March 23, 2010


Transcept Pharmaceuticals Granted Second U.S. Patent Covering Intermezzo® Formulation
March 23, 2010


WorldHeart Announces Levacor VAD Implant at the University of Utah
March 23, 2010


Prometheus and Bayer Schering Pharma to Apply Novel Diagnostic Platform to Oncology Therapeutic Candidates
March 17, 2010


Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide™ in Japan
March 10, 2010


ISTA Pharmaceuticals Receives Action Date for FDA Review of Once-Daily XiDay™
March 8, 2010


Auxilium Announces Availability of XIAFLEX™ for the Treatment of Dupuytren's Contracture
March 8, 2010


NxStage Announces New FREEDOM Data Showing the Positive Impact of its Daily Home Hemodialysis Therapy on Sleep Quality and Restless Legs Syndrome
March 8, 2010


ReShape Medical Announces Initiation of U.S. Clinical Study for Weight Loss
March 3, 2010


NxStage® and Dirinco Sign Distribution Agreement For System One™ in the Netherlands
March 2, 2010


Tioga Pharmaceuticals, Inc. Raises $18 Million to Fund Phase 3 Clinical Trial in Irritable Bowel Syndrome
February 17, 2010


Transcept Pharmaceuticals Granted First U.S. Patent Covering Intermezzo® Formulation
February 9, 2010


Auxilium Announces U.S. Food and Drug Administration Approval for XIAFLEX™ for the Treatment of Dupuytren's Contracture
February 3, 2010


NxStage® and Nordic Medcom Sign Distribution Agreement for the System One™
February 3, 2010


Pearl Therapeutics Raises $15 Million to Advance PT003, LAMA/LABA Combination Bronchodilator for COPD, into Phase 2b Study
February 1, 2010


World Heart Corp. Completes $7.3 Million Private Placement
January 26, 2010


Prometheus Acquires Exclusive Rights to PROLEUKIN® (aldesleukin) in the U.S.
January 26, 2010


Labcyte Expands Acoustic Dispensing and Launches Into New Markets
January 26, 2010


Affymax Completes Treatment and Last Patient Follow-up in Phase 3 Program for Investigational Drug, Hematide™, to Treat Anemia in Chronic Renal Failure
January 25, 2010


Pfizer and Auxilium Announce Commencement of European Regulatory Review of XIAFLEXTM for the Treatment of Dupuytren's Contracture
January 21, 2010


WorldHeart Announces First U.S. Implant of Levacor™ VAD Implant at INTEGRIS in Oklahoma City
January 19, 2010


ISTA Pharmaceuticals announces trial results for topical Xibrom 0.09%
January 11, 2010


WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor™ VAD
January 8, 2010


Tolerx Completes Enrollment in DEFEND-1, a Phase 3 Type 1 Diabetes Study with Otelixizumab
January 7, 2010


Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
January 7, 2010


Prometheus Completes $260 Million Financing
January 7, 2010


Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Glycopyrrolate Inhalation Aerosol in Chronic Obstructive Pulmonary Disease
January 6, 2010


Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Formoterol Inhalation Aerosol in Chronic Obstructive Pulmonary Disease
January 4, 2010